Tumorigenesis and breast cancer progression induced by HMGB1 as a ligand may be mediated via the TLR4/myeloid differentiation factor 88 and RAGE signaling pathways for tumor invasion and metastasis, CSC renewal, epithelial–mesenchymal transition (EMT), drug resistance, and cancer recurrence [73,74]. Here, HMGB1 is linked to breast cancer.